Skip to content

Technology

IP

Proacta holds a patient portfolio covering several classes of hypoxia-targeted prodrugs for the treatment of cancer. Expansion of the portfolio is supported through funded research led by acknowledged international experts in the field at the University of Auckland and Stanford University. Proacta's strong IP and ongoing research activities in hypoxia-targeted cancer therapies give it a leadership position in the cancer hypoxia field.

Back to top

  • Alta Partners
  • Cancer Society
  • Clarus
  • Delphi Ventures
  • Endeavour Capital
  • GBS
  • Genentech
  • No. 8 Ventures
  • Roche
  • UniServices
  • The University of Auckland